Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Apaziquone Fails Pivotal Trial

By Drug Discovery Trends Editor | April 5, 2012

HENDERSON, Nev. (AP) – Drugmaker Spectrum Pharmaceuticals announced that a potential cancer treatment it is developing has missed its main goal in late-stage testing.

The Henderson, Nev., company also said it signed an agreement to acquire Allos Therapeutics Inc. in a deal valued at up to $206 million.

On the drug test, Spectrum said two clinical trials of its potential bladder cancer treatment apaziquone failed to show a statistically significant difference in the rate of tumor recurrence at two years. But the company said pooled data from the studies did show a statistically significant treatment effect.

The company may meet with the Food and Drug Administration to discuss future steps.

In its acquisition, Spectrum said it will pay $1.82 per share for each outstanding share of Allos.

Allos shareholders also will receive a contingent value right to an additional payment of 11 cents per share if it achieves some European regulatory and commercialization milestones for the cancer drug Folotyn.

The boards of directors for both companies have unanimously approved the deal.

Folotyn is approved in the U.S. as a treatment for peripheral T-cell lymphoma in patients who have suffered a relapse or who have not responded to previous treatment.

Spectrum sells two oncology drugs, Zevalin, which is approved to treat a form of non-Hodgkin’s lymphoma, and Fusilev, which treats the side effects of methotrexate, a drug used in chemotherapy.

Spectrum Chairman and CEO Dr. Rajesh C. Shrotriya said in a statement the deal accelerates its hematology franchise development and “affirms our commitment to becoming a leader in the treatment of lymphoma.”

Date: April 4, 2012
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE